Cytomegalovirus (CMV) infection of simian virus 40 (SV40)-immune mice inhibits priming of SV40-specific helper and cytotoxic T lymphocytes (CTL) in vivo (A. E. Campbell, J. S. Slater, and W. S. Futch, Virology 173:268-275, 1989; J. S. Slater, W. S. Futch, V. J. Cavanaugh and A. E. Campbell, Virology 185:132-139, 1991). We now demonstrate that murine CMV (MCMV) infection of SV40-transformed macrophages and fibroblasts prevents presentation of SV40 T antigen to SV40-specific CTL. MCMV-infected macrophages failed to stimulate SV40-immune CTL precursors in vitro. In addition, MCMV-infected, SV40-transformed macrophage and fibroblast target cells lost their susceptibility to lysis by major histocompatibility complex class I-restricted, SV40-specific CTL clones. MCMV infection did not alter the synthesis of SV40 T antigen in the target cells. MCMV early gene expression was required for inhibition of SV40 T-antigen presentation;
Our previous studies aimed to identify mechanisms of cytomegalovirus (CMV)-induced suppression of cell-mediated immunity. We demonstrated that acute infection of simian virus 40 (SV40)-immune mice prevents priming of SV40-specific cytotoxic T-lymphocyte (CTL) precursors (6) . This occurs when murine CMV (MCMV) infection either precedes or follows SV40 immunization. Continued studies by Slater et al. revealed that priming of T-helper lymphocytes in response to SV40 immunization is also disrupted by MCMV infection (24) . Lack of T-helper cell function in MCMV-infected mice does not, however, explain the deficiency in CTL priming, as this latter event is T-helper cell independent (24) . Therefore, MCMV infection must inhibit an event common to cytotoxic and helper T-lymphocyte priming, such as antigen presentation.
Elegant studies by Del Val et al. (7) describe a selective inhibition in presentation of MCMV immediate-early (IE) protein, pp89, to H-2Ld-restricted, pp89-specific CTL clones. An MCMV early (E) gene product is responsible for this effect. E gene expression does not affect the synthesis or stability of pp89, and there is no concomitant alteration in expression of major histocompatibility complex (MHC) class I molecules. This was the first indication that an MCMV protein(s) could interfere with the process of antigen presentation. We questioned whether such inhibition in antigen presentation by MCMV is selective for MCMV peptides or whether presentation of other cellular peptides is also affected by the virus. This is an important question, because in vivo, MCMV infects macrophages and other antigen-presenting cells (3, 20, 22) .
We addressed the question of whether MCMV interferes with presentation of normal host cell proteins by assessing the effects of MCMV infection of SV40-transformed cells on the ability of these cells to present SV40 T antigen to * Corresponding author. SV40-specific, MHC class I-restricted CTL. SV40 T antigen is constitutively expressed in the transformed cells and thereby mimics a host cell protein. The T antigen is processed into at least five distinct peptide determinants which are recognized by SV40 CTL (see reference 28 for a review).
We tested the effects of MCMV infection of SV40-transformed macrophages and fibroblasts on presentation of SV40 T antigen to SV40-specific CTL and determinant-specific CTL clones. The data indicate that an MCMV E gene product prevents presentation of T antigen to CTL. This inhibition does not rely on a reduction in surface MHC class I molecules, although an MCMV E gene product(s) does reduce surface MHC expression. Furthermore, MCMV infection has no effect on the synthesis of SV40 T antigen in the transformed cells. MCMV proteins expressed in infected, SV40-transformed cells are presented to MCMVspecific CTL when SV40 T antigen is not presented. Therefore, MCMV infection interferes with processing and/or presentation of cellular proteins by some mechanism independent of reduced surface MHC expression.
MATERUILS AND METHODS
Cells. SV40-transformed H-2b fibroblasts (designated WT-19) and SV40-transformed H-2d fibroblasts (mKSA) were obtained from Satvir S. Tevethia (Pennsylvania State University College of Medicine) and maintained as previously described (6) . SV40-transformed H-2"-macrophages (IC-21) were obtained from the American Type Culture Collection (Rockville, Md.) and were maintained as previously de- scribed (19) . SV40-specific H-2Db-restricted CTL clones Kll and K19 have been previously described (5) .
Virus. Preparation of salivary gland-derived MCMV and tissue culture-passaged stocks has been described (6 selectively restrict MCMV replication has previously been described (7) . Briefly, cells were treated with 250 ,ug of PAA per ml at the time of virus infection for a duration of 24 h. Cells were treated with 50 ,ug of CH per ml at the time of infection for a total of 3 h. CH was subsequently washed from the cells, and incubation continued for another 4 h either in media alone (CH/-) or in media containing 100 ,ug of ActD per ml (CH/ActD).
CTLp frequency analysis. Detailed procedures for SV40 CTL precursor (CTLp) frequency analysis have been described previously (6) . Briefly, limiting numbers of SV40-immune lymph node cells (LNC) were cultured for 7 days with mitomycin-treated WT-19 stimulator cells, irradiated splenocytes as filler cells, recombinant interleukin-2 (rIL-2), and other growth factors.
Cytotoxicity assays. 51Cr-release cytotoxicity assays were performed as previously described (26) . All (14) and were separated on a 10% polyacrylamide gel as previously described (25) . Steady-state levels of SV40 T antigen. Lysates from equal numbers of mock-infected and MCMV-infected WT-19 cells were analyzed with antibody PAb901 by Western immunoblot as previously described (21) . Primary antibody binding was detected by using alkaline phosphatase-conjugated goat anti-mouse antibody (Promega Biotec, Madison, Wis.) and bands were visualized by chemiluminescence according to manufacturer's instructions (Tropix, Bedford, Mass.).
RESULTS
Effects of MCMV infection on presentation of SV40 T antigen to SV40 CTL. Our earlier studies (6, 24) Results from a second series of experiments further indicated that MCMV infection inhibits MHC class I-restricted presentation of SV40 T antigen to SV40 CTL. MCMVinfected, SV40-transformed IC-21 macrophages and WT-19 fibroblasts were tested for their susceptibilities to lysis by SV40-specific, H-2Db-restricted CTL clones Kll and K19. These CTL clones recognize two distinct determinants on the amino terminus of SV40 T antigen, sites I and II, respectively (1, 28) . The data in Fig. 1 The use of CHIActD and CH/-distinguished the relative roles of MCMV IE and E proteins in regulating antigen presentation. MCMV E proteins were clearly involved in suppression of antigen presentation, since suppression was significant when target cells were treated with CH without subsequent ActD treatment (Fig. 2c) . Suppression was minimal when replication was restricted to the IE phase with CH/ActD treatment (Fig. 2d) . It is important to note that CH-and CH/ActD-treated cells were infected with MCMV for a total of only 7 h, compared with the 24-h infection of PAA-treated cells. This explains the differences in the magnitude of suppression of lysis by MCMV infection in the presence of PAA versus CH/-and CH/ActD. The half-life of peptide-MHC complexes on the cell surface is approximately 14 h. Therefore, preexisting SV40 T peptide-MHC complexes are contributing to the lysis of target cells infected with MCMV for 7 but not 24 h. Collectively, the above data indicate that MCMV E proteins are required for maximal inhibition of class I-mediated antigen presentation. These results also eliminate at least a direct role for input virion proteins in inhibiting antigen presentation.
Presentation of MCNV antigens to MCMV-specific CTL. Because MCMV E proteins appeared to be involved in regulating expression of surface SV40 T antigen-MHC complexes, we tested the infected target cells for presentation of MCMV antigens. The same population of SV40-transformed, MCMV-infected cells used in experiments in Fig. 2 was also used as targets of MCMV-immune CTL. The results in Fig. 3 indicate that MCMV antigens were indeed presented on the surface of cells proven to be devoid of SV40 T-antigen recognition. Again, MCMV E proteins, as opposed to IE or L viral proteins, were the major determi- nants recognized by H-2b MCMV-specific CTL. MCMVinfected target cells treated with PAA (Fig. 3b) or CH/- (Fig. 3c) were competent targets, whereas CH/ActD-treated cells (Fig. 3d) However, it remained possible that MCMV infection suppressed MHC class I expression and that limited MHC molecules favored competition between MCMV and SV40 T-antigen peptides. MHC class I expression was quantitated on the surface of MCMV infected, WT-19 fibroblasts treated with gamma interferon for various time periods. The data in Table 2 indicate that MCMV infection suppresses MHC surface expression unless gamma interferon treatment continues throughout infection. Also, the degree of suppression depended on the quantity of MHC expressed prior to infection. For example, MHC expression on cells treated with interferon for 48 h prior to infection was less affected by virus infection compared with that of cells treated with interferon for only 24 h and expressing suboptimal levels of MHC class I. Most importantly, the results indicate that inhibition of SV40 T-antigen presentation on MCMV-infected cells occurs independently of alterations in MHC class I expression. MCMV-infected target cells used in all cytotoxicity experiments were treated with gamma interferon 24 h prior to and 24 h during MCMV infection. As shown in Table 2 , this treatment does not result in significant reduction in surface MHC heavy or light chain molecules. a Surface immunofluorescence was determined by using the following primary antibodies: H-2D", 28-14-8S; H-2Kf', Y-3; P2m, Ly-mll and fluorescein isothiocyanate-labeled goat anti-mouse IgG and IgM. b Mock-(MOCK) and MCMV-infected (MCMV) (1 PFU per cell) SV40-transformed fibroblasts were treated with PAA or control media (None) at the time of infection for a 24-h duration. Other target cells were treated with CH (CH/-) or CH followed by ActD (CH/ActD) as described in Materials and Methods. Cells treated with CH and CH/ActD were infected for a total of 7 h.
We further questioned the relative roles of MCMV IE, E, or L gene products in downregulating surface MHC expression. cells were pretreated for 24 h with gamma interferon and then infected with MCMV in the presence of the various drugs described above. The results in Table 3 indicate that MCMV E protein expression was required for maximal suppression of MHC expression. However, results with CH/-and CH/ActD treatments are difficult to interpret, because these drugs affected MHC expression on mock-infected cells and the percentage of cells expressing the MHC molecules was low.
Effects of MCMV infection on expression of SV40 T antigen. One possible explanation for a reduction in presentation of SV40 T antigen, independent of MHC class I expression, is downregulation of SV40 T-antigen expression by MCMV gene products. Processed peptides recognized by SV40 CTL are likely derived from newly synthesized SV40 T antigen. Therefore, we compared the synthesis of T antigen in WT-19 cells at various stages of MCMV infection. Radiolabeled cell lysates were prepared at 3 (IE), 8 (E), and 24 (L) h after MCMV infection (7) and were analyzed by immunoprecipitation with a monoclonal antibody (PAb901) specific for the carboxy terminus of SV40 T antigen.
The results in Fig. 4 represent immunoprecipitations of lysates, based on trichloroacetic acid-precipitable counts. MCMV infection at IE, E, and L times did not decrease the synthesis of SV40 T antigen relative to total radiolabeled cell protein. When the experiment was repeated with equal volumes of cell lysates, again no MCMV-induced reduction in the expression of T antigen was observed (data not shown). In fact, the data in Fig. 4 suggest that synthesis of T antigen increases early to late in infection. This is consistent with the studies of Pari and St. Jeor (21) , who demonstrated that the major IE protein of human CMV (HCMV) causes an increase in the expression of SV40 T antigen.
We also compared the steady-state levels of SV40 T antigen in mock-infected and MCMV-infected cells by Western blot analysis. The results in Fig. 5 indicate that MCMV infection for 24 h did not appreciably alter the steady-state level of this 92-to 95-kDa protein. The limitation of this method is that subtle changes in the stability of T antigen would not be detected by this method, because the half-life of T antigen in these transformed cells is approximately 22 h (28a). However, it was previously shown that even a major reduction in the stability of SV40 T antigen (to 40 min) has no effect on CTL recognition (29) . DISCUSSION The results from this study support our initial hypothesis, based on in vivo data, that MCMV infection interferes with antigen presentation. The findings of the present in vitro studies are likely applicable to the in vivo situation in which MCMV infection of mice prevents priming of helper T lymphocytes (24) and CTL (6) . The results demonstrate that MCMV infection interferes with presentation of endogenously synthesized peptides. Antigen-presenting cells, such as macrophages and stromal cells of lymphoid organs, are permissive for productive and latent MCMV infection in vivo (3, 20, 22) . MCMV infection could interfere with presentation of normal cellular peptides and with peptides from other infectious agents coinfecting these cells. This is an important consideration for HCMV as well, because HCMV productively infects macrophages (15) and suppresses antigen-specific, MHC-restricted CTL activity (23) .
Virus-induced perturbation in antigen-presenting functions has been reported for influenza virus (8) Because MCMV E gene products are involved in suppression of SV40 T-antigen presentation and at the same time are themselves presented to MCMV-specific CTL, it is tempting to speculate that these viral gene products compete with SV40 T-antigen peptides for presentation by MHC class I molecules. Such a mechanism of competition between viral peptides for presentation at the cell surface has recently been proposed for vaccinia virus and lymphocytic choriomeningitis virus (4). However, it remains to be determined whether the same MCMV E proteins involved in suppression of antigen presentation are indeed the same viral proteins presented on the cell surface. The precise role of MCMV proteins in regulating antigen presentation is currently under investigation.
